FDA Approves Bristol Myers Squibb’s COBENFY for Adult Schizophrenia
Bristol Myers Squibb (NYSE: BMY) has received approval from the U.S. Food and Drug Administration (FDA) for COBENFY™ (xanomeline and trospium chloride), marking a significant advancement in the treatment of…
FDA Approves Dupixent as the First Biologic Treatment for COPD in the U.S
The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype and…
Tagrisso Receives U.S. Approval for Unresectable Stage III EGFR-Mutated Lung Cancer Patients
AstraZeneca’s Tagrisso (osimertinib) has received U.S. approval for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), whose disease has…
Roche’s Gazyva Shows Superior Phase III Results in Lupus Nephritis Treatment
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III REGENCY study of Gazyva®/Gazyvaro® (obinutuzumab) in patients with active lupus nephritis. The study revealed that…
Merck Updates on Phase 3 Trial of Favezelimab-Pembrolizumab Combo in Colorectal Cancer
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the Phase 3 KEYFORM-007 trial, which investigated the fixed-dose combination of favezelimab (Merck’s anti-LAG-3 antibody) and…
BioAlberta and AxialBridge Partner to Help Alberta Life Sciences Companies Expand into the UK
BioAlberta is excited to announce a new partnership with AxialBridge as its operational and commercialization partner. This collaboration aims to assist Alberta-based biotechnology and MedTech companies in expanding their clinical…
eClinical Solutions Pioneers the Future of Drug Development at ENGAGE 2024 Conference
eClinical Solutions LLC, a global leader in digital clinical software and services, is set to host its sixth annual client and partner conference, ENGAGE 2024, on Thursday, October 10 and…
Phare Bio Secures Up to $27M from ARPA-H for AI-Driven Antibiotic Development
Phare Bio, in collaboration with the Collins Lab at the Massachusetts Institute of Technology (MIT) and Harvard’s Wyss Institute, has secured up to $27 million in funding from the Advanced…
BeiGene Updates on FDA Advisory Vote for PD-1 Inhibitors, Including TEVIMBRA, in ESCC and Gastric/GEJ Cancers
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized the positive…
FDA Approves Bristol Myers Squibb’s COBENFY for Adult Schizophrenia Treatment
Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for treating schizophrenia in adults.…
New Study Assesses Awareness of High Breast Density as a Breast Cancer Risk Factor
In recognition of World Dense Breast Day on September 25, Bayer has announced a new study, published in Patient Preference and Adherence, that explores gaps in awareness and knowledge of…
BC Patients Neglected as Province Falls Short on Essential Medication Coverage
As British Columbians head to the polls on October 19, the Gastrointestinal Society is drawing attention to a critical issue: BC PharmaCare’s refusal to fund over 30 essential medications that…